What percentage HLA (human leukocyte antigen) match is required for a bone marrow donor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HLA Matching Requirements for Bone Marrow Donors

For unrelated bone marrow donors, an 8/8 HLA match (100% match at HLA-A, HLA-B, HLA-C, and HLA-DRB1 at high-resolution) is the optimal standard and is associated with the highest survival rates. 1

Understanding the Match Percentage

The matching is not expressed as a simple percentage but rather as a fraction of matched alleles:

  • 8/8 match (optimal): Complete matching at all four critical loci (HLA-A, HLA-B, HLA-C, HLA-DRB1), representing 100% match at these core loci
  • 7/8 match (acceptable): One allele mismatch, associated with reduced survival (43% vs 52% one-year survival for 8/8 matches) 2
  • 6/8 or less: Multiple mismatches that significantly worsen outcomes and generally do not provide acceptable survival under conventional transplant practices 1

Critical Matching Algorithm

Primary matching requirements 1:

  • High-resolution DNA-based typing required for HLA-A, HLA-B, HLA-C, and HLA-DRB1
  • All four loci must match at the allele level (2-field typing)
  • HLA-DPB1 should be matched or have permissive mismatches when possible

When 8/8 match is unavailable 1:

  • A 7/8 match is acceptable but carries increased mortality risk (relative risk 1.25) 2
  • Younger donor age becomes the next priority
  • Minimize additional mismatches at HLA-DRB3/4/5 and HLA-DQB1
  • Avoid mismatches targeted by donor-specific antibodies

Important Clinical Nuances

HLA mismatching consistently associates with 1:

  • Inferior recipient survival in both myeloablative and reduced-intensity conditioning
  • Increased acute and chronic graft-versus-host disease
  • Higher treatment-related mortality
  • The greatest negative impact occurs in patients with early-stage disease

Common pitfall: Any single mismatch at HLA-A, HLA-B, HLA-C, or HLA-DRB1 significantly worsens outcomes, with no evidence that mismatch at any individual locus is better tolerated than others 1. Multiple mismatches compound this risk exponentially.

Alternative Donor Options

When an 8/8 matched unrelated donor is unavailable, alternative options include 1:

  • 7/8 matched unrelated donors (with careful selection criteria)
  • Haploidentical related donors (50% match, or 5/10)
  • Umbilical cord blood (can tolerate greater HLA disparity)

These alternatives are viable options when no 8/8 match exists, though individual patient factors (disease risk, urgency, donor availability) influence the final selection. 1

References

Related Questions

What is the minimum number of Human Leukocyte Antigen (HLA) compatibilities required for a transplant?
When should magnetic resonance venography (MRV) be ordered?
Does Vitamin D3 (cholecalciferol) have a role in the management of neonatal jaundice?
Should an asymptomatic, non‑pregnant patient who tests positive for Ureaplasma and has no infertility work‑up, no immunocompromise, and is not scheduled for urologic or obstetric surgery be treated?
Can a 22-year-old patient take risperidone and tetrahydrocannabinol (THC) together?
What oral antibiotic (dose and duration) is appropriate for a 67-year-old woman with acute bacterial sinusitis, a penicillin allergy, recent use of nitrofurantoin (Macrobid), a macrolide (azithromycin) and doxycycline in the past six months, and an estimated glomerular filtration rate of 69 mL/min?
What are the differential diagnoses for bilateral hip pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.